PLCB4 and colorectal carcinoma: This highlights the potential of CDKN2A as a prognostic marker for aggressive disease, while PLCB4 and NXPE4 may act as favorable prognostic indicators, indicating their distinct functions in the progression of CRC and patient outcomes.